Related Experiment Videos
Cost-effectiveness analysis in heart disease, Part III: Ischemia, congestive heart failure, and arrhythmias
J Kupersmith1, M Holmes-Rovner, A Hogan
1Department of Medicine, College of Human Medicine, Michigan State University, East Lansing 48824.
Insights
Cost-effectiveness of cardiac interventions varies. Acute myocardial infarction treatments like thrombolysis and ACE inhibitors are cost-effective, while coronary artery bypass graft surgery benefits specific conditions. Implantable cardioverter defibrillators for arrhythmias are also cost-effective.
Area of Science:
- Cardiovascular medicine
- Health economics
- Clinical decision-making
Background:
- Cost-effectiveness analyses are crucial for guiding clinical practice and resource allocation in cardiovascular disease management.
- Evaluating the economic value of diagnostic and therapeutic strategies ensures optimal patient outcomes and healthcare system efficiency.
Purpose of the Study:
- To review and synthesize the cost-effectiveness of various diagnostic and treatment strategies for acute myocardial infarction (MI), coronary artery disease (CAD), and arrhythmias.
- To identify cardiovascular interventions that offer significant health benefits relative to their costs.
Main Methods:
- Systematic review of cost-effectiveness analyses across multiple cardiovascular disease categories.
- Categorization of interventions including coronary care units, thrombolysis, pharmacotherapy (beta-blockers, ACE inhibitors), CAD screening, coronary artery bypass graft (CABG) surgery, percutaneous transluminal coronary angioplasty (PTCA), cardiac transplant, and arrhythmia treatments.
Main Results:
- Coronary care units can be more efficient with better triage. Thrombolysis, beta-blockers, and ACE inhibitors post-MI are cost-effective.
- Cost-effectiveness of CAD screening is prevalence-dependent. CABG and PTCA are cost-effective for specific severe conditions.
- ACE inhibition for congestive heart failure (CHF) dominates (saves lives and money). Implantable cardioverter defibrillators and radiofrequency ablation for arrhythmias are cost-effective.
Conclusions:
- Specific interventions like thrombolysis, ACE inhibitors for MI and CHF, CABG/PTCA for severe CAD, and certain devices for arrhythmias demonstrate cost-effectiveness.
- Resource utilization and patient selection are key factors in maximizing the cost-effectiveness of cardiovascular treatments.
- Further research is needed for cardiac transplant and some pacemaker applications to fully establish their economic value.
Abstract:
Cost-effectiveness analyses were reviewed in the following diagnostic and treatment categories: acute myocardial infarction (MI) and diagnostic strategies for coronary artery disease (CAD), coronary artery bypass graft (CABG) surgery, percutaneous transluminal coronary angioplasty (PTCA), congestive heart failure (CHF), and arrhythmias. In the case of acute MI, coronary care units, as presently used, are rather expensive but could be made much more efficient with more effective triage and resource utilization; reperfusion via thrombolysis is cost-effective, as are beta-blockers and angiotensin-converting enzyme (ACE) inhibitors post-MI in appropriate patients. Cost-effectiveness of CAD screening tests depends strongly on the prevalence of disease in the population studied. Cost-effectiveness of CABG surgery depends on targeting; eg, it is highly effective for such conditions as left-main and three-vessel disease but not for lesser disease. PTCA appears to be cost-effective in situations where there is clinical consensus for its use, eg, severe ischemia and one-vessel disease, but requires further analysis based on randomized data; coronary stents also appear to be cost-effective. In preliminary analysis, ACE inhibition for CHF dominates, ie, saves both money and lives. Cardiac transplant appears to be cost-effective but requires further study. For arrhythmias, implantable cardioverter defibrillators are cost-effective, especially the transvenous device, in life-threatening situations; radiofrequency ablation is also cost-effective in patients with Wolff-Parkinson-White syndrome apart from asymptomatic individuals; and pacemakers have not been analyzed except in the case of biofascicular block, where results were variable depending on the situation and preceding tests.